KOSDAQBiotech & Pharma456070

ENCell

₩4,030▼ 3.13%2026-11-18 close
Market Cap
₩44.4B
Turnover
₩200M
Volume
50K
Shares out.
11M
PER
—
PBR
2.1×
EPS
-₩1,983
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Shrinking Sales and Losses; EN001 and AAV Orders in Focus

ENCell's revenue fell in 2024 and 2025 while operating losses widened. Sales have risen for two straight quarters through Q3 2026, but an operating loss of KRW 5.02 billion keeps the focus on EN001 and AAV orders.

  1. 1

    Revenue fell from KRW 10.5 billion in 2023 to KRW 5.26 billion in 2025, declining for two straight years in 2024 and 2025.

  2. 2

    The 2025 operating loss reached KRW 17.9 billion, up from KRW 11.8 billion in 2023, and the operating margin was -340.4%.

  3. 3

    Q3 2026 revenue of KRW 1.71 billion rose for two straight quarters, but the company has posted losses for five straight quarters, including an operating loss of KRW 5.02 billion in Q3 2026.

  4. 4

    A KRW 22.5 billion convertible bond was issued in December 2025, and the debt-to-equity ratio rose to 61.7% at the end of 2025 from 15.7% in 2024.

  5. 5

    EN001 dosed its first patient in the Phase 2a trial in May 2026, and data are expected in early 2027.

02

Business structure

ENCell is a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) that also develops new drugs. It listed on KOSDAQ through the technology-special-listing route in August 2024.

According to a report based on Financial Supervisory Service electronic disclosures, 100% of revenue comes from CDMO work. Effective January 1, 2026, the company reorganized into four divisions: New Drug R&BD, Advanced Regenerative Bio, CDMO, and Anti-aging.

The reorganization prioritizes commercializing its own pipeline over making products for clients. Within CDMO, clinical-grade production for AAV (adeno-associated virus) gene therapies is the core.

In July 2025 the company won a KRW 5.7 billion project from the Korea Research Institute of Bioscience and Biotechnology to build a clinical production platform for custom AAV gene therapies, a medium-term project running through 2029.

In October 2026 it was designated a commercial central cell processing center for a global pharma company's CAR-T therapy. Its main pipeline asset is EN001, a mesenchymal stem cell therapy in a Phase 2a trial for Charcot-Marie-Tooth disease type 1A (CMT1A).

In May 2026 the regenerative medicine unit received Japan's MHLW certification for a specified cell processing facility and is preparing to enter the Japanese market. The anti-aging division is building autologous stem cell regenerative medicine and skin booster businesses as new revenue sources.

The company claims a leading position in CGT share and sales, but its revenue scale is far smaller than large CDMOs such as Samsung Biologics.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.5B-₩3.7B−240.8%
2025Q4₩1.4B-₩4.9B−342.7%
2026Q1₩300M-₩4.9B−1576.4%
2026Q2₩900M-₩4.7B−539.0%
2026Q3₩1.7B-₩5B−293.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩10.5B-₩11.8B-₩5.1B−111.7%−13.3%15.7%
2024₩7.2B-₩15.7B-₩15.2B−217.5%−31.6%15.7%
2025₩5.3B-₩17.9B-₩16.1B−340.4%−40.9%61.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 10.5 billion in 2023 to KRW 7.21 billion in 2024 (down 31.5% year on year) and KRW 5.26 billion in 2025 (down 27.1% year on year). Revenue declined for two straight years in 2024 and 2025; 2023 was the largest year and 2025 the smallest in the 2023-2025 period.

Over the same span the operating loss widened from KRW 11.8 billion to KRW 15.7 billion and then KRW 17.9 billion, and the operating margin moved from -111.7% to -217.5% and then -340.4%.

For the first nine months of 2025, the company said some CDMO project revenue was recognized later in the year, while R&D spending rose from KRW 4.7 billion to KRW 5.6 billion as EN001 progressed. It also cited industry-wide clinical delays and weaker biotech investment as reasons for fewer client orders.

Media reported the 2025 operating loss of KRW 17.9 billion as the largest annual loss on record. At the end of 2025, total equity of KRW 39.4 billion was entirely attributable to controlling shareholders, and total liabilities were KRW 24.3 billion.

Operating cash flow was KRW -6.44 billion in 2023, KRW -10.1 billion in 2024, and KRW -10.2 billion in 2025. Net loss attributable to controlling shareholders grew from KRW 5.05 billion in 2023 to KRW 15.2 billion in 2024 and KRW 16.1 billion in 2025.

Quarterly revenue fell from KRW 1.55 billion in Q3 2025 and KRW 1.44 billion in Q4 2025 to KRW 309 million in Q1 2026, then rose to KRW 868 million in Q2 2026 and KRW 1.71 billion in Q3 2026.

Operating losses over the same quarters were KRW 4.87 billion in Q1 2026, KRW 4.68 billion in Q2 2026, and KRW 5.02 billion in Q3 2026, and the Q3 2026 loss widened year on year even as revenue rose 10.7%.

Net loss attributable to controlling shareholders peaked at KRW 7.23 billion in Q2 2026 among the last five quarters and narrowed to KRW 5.78 billion in Q3 2026. The four quarters from Q4 2025 through Q3 2026 total KRW 21.8 billion in net losses attributable to controlling shareholders.

05

Industry analysis

The CGT CDMO market is sensitive to clients' clinical timelines and biotech investment sentiment. The company has said that clinical delays and weaker investment since 2024 reduced client orders.

In its April 2026 earnings commentary, it also cited a prolonged medical strike as a reason for clinical delays at key clients. The company nonetheless believes conditions in the CDMO market have improved compared with earlier. On the demand side, inquiries and order talks for AAV-based gene therapy CDMO are growing.

The company also expects demand for investigator-initiated clinical production to rise under the amended Advanced Regenerative Bio Act. NH Investment & Securities expected a second-half recovery in the industry after weak CDMO results in the first quarter of 2026, but said order momentum had been absent.

Competitively, large CDMOs have an edge in production capacity and client portfolio scale, while ENCell is concentrating on niches such as AAV clinical-grade manufacturing and CAR-T cell processing. The pace of the industry recovery and clients' clinical timelines are the key variables for CDMO earnings.

06

Outlook

In April 2026 the company said it expects CDMO revenue to return to growth and that new businesses, including Japanese regenerative medicine and cosmetics, will generate revenue from the second half.

In its January 2026 reorganization it created a new sales team within the CDMO division and plans to expand production capacity focused on AAV.

Production for the AAV clinical manufacturing project with the Korea Research Institute of Bioscience and Biotechnology is expected to ramp up, and talks on investigator-initiated clinical production orders and overseas clients are ongoing.

In Japan, the company received MHLW certification in May 2026, and in October 2026 it indicated that regenerative medicine would become full-scale in 2027.

NH Investment & Securities expected first advanced regenerative revenue in the second half of 2026, described the 2026 sales target as in the low KRW 1 billion range, and expected a full-scale revenue ramp from 2027. EN001 dosed its first patient in the Phase 2a trial in May 2026, and data are expected in early 2027.

The company said it is in talks with several global companies on technology transfer but has not given a timeline for a deal.

The 2026 targets set around the IPO, KRW 38.0 billion in revenue and KRW 600 million in operating profit as a turn to profitability, cannot be treated as current guidance, because the company said it would not issue separate guidance after market conditions changed.

07

Valuation

PER
—
PBR
2.1×
ROE
-74.4%
EPS
-₩1,983
BPS
₩2,036
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. The price-to-book ratio is above 1, meaning the stock trades at a premium to book value.

That premium can be read as the market pricing in value beyond book equity, such as the pipeline and order prospects. Without an earnings base, PER comparisons with industry peers are of limited use, and the gap in sales scale and earnings capacity versus listed peers makes multiple comparisons less meaningful.

The dividend yield is low, so dividend-based comparisons do not apply. On the balance sheet, all KRW 39.4 billion of equity at the end of 2025 is attributable to controlling shareholders, but total liabilities rose to KRW 24.3 billion, raising debt burden.

Losses have persisted for three straight years from 2023, and widened in 2024 and 2025, so narrowing the gap between book value and price depends on whether losses shrink. The fact that the operating profit target presented at the IPO was not met also forms part of the context for valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Wider CDMO Order Base in AAV and CAR-T

The order backlog rose to KRW 9.1 billion at the end of Q3 2025, from KRW 4.0 billion at the end of 2024 and KRW 5.0 billion at mid-2025. The company said new orders reached KRW 10.0 billion in 2025, and the AAV clinical production project with KRIBB runs through 2029.

In October 2026 it was designated a commercial central cell processing center for a global pharma company's CAR-T therapy, widening its role from clinical to commercial work.

EN001 Clinical Progress and Orphan Designations

NH Investment & Securities reported that EN001's repeated-dosing Phase 1b results showed statistically significant improvement in key efficacy indicators. The company dosed its first patient in the Phase 2a trial in May 2026.

Following a US FDA orphan drug designation, the European Medicines Agency granted orphan designation in May 2026, and the company said it is in technology transfer talks with several global companies.

Japanese Regenerative Certification and Business Diversification

The company received MHLW certification for a specified cell processing facility in May 2026, and in October 2026 it indicated regenerative medicine would become full-scale in 2027.

The anti-aging division is built on autologous stem cell regenerative medicine and skin boosters, and in August 2026 the company announced an anti-aging ingredient listing in an international cosmetics ingredient database. The new businesses are framed as a way to reduce reliance on CDMO revenue.

09

Bear factors

Falling Sales and Widening Losses at Once

Revenue fell from KRW 10.5 billion in 2023 to KRW 5.26 billion in 2025, while the operating loss widened from KRW 11.8 billion to KRW 17.9 billion over the same period. The 2025 operating margin was -340.4%.

Media reported that results fell short of the 2024 and 2025 revenue targets presented at the IPO, which were KRW 18.8 billion and KRW 22.7 billion respectively.

Convertible Bonds and Rising Debt Burden

Media reported that the company issued its first convertible bond, worth KRW 22.5 billion, in December 2025. The debt-to-equity ratio rose from 15.7% in 2024 to 61.7% in 2025, and operating cash flow was KRW -10.2 billion in 2025. The company said the bond proceeds are for EN001 clinical development.

Persistent Quarterly Losses and Cost Pressure

The company has posted operating losses for five straight quarters from Q3 2025 through Q3 2026. The Q3 2026 operating loss of KRW 5.02 billion widened year on year, and higher Q3 revenue did not translate into a smaller loss.

Net loss attributable to controlling shareholders totals KRW 21.8 billion over the last four quarters. It did narrow to KRW 5.78 billion in Q3 2026 from KRW 7.23 billion in Q2 2026.

10

Risk factors

Listing Maintenance · Pre-tax Loss Rule

Under the Korea Exchange pre-tax loss from continuing operations rule, the risk of a management issue designation has been raised. One report said the grace period ends at the end of 2026, while another said designation applies from 2027, three years after listing, if the ratio is exceeded. Because the two reports differ on timing, the underlying disclosure criteria need to be checked directly.

Clinical Trials · Technology Transfer

EN001 is in Phase 2a with data expected in early 2027, but the Phase 2a results and any technology transfer deal are not yet settled. Clinical delays have been cited as a cause of deferred CDMO revenue since 2024.

The full launch of Japanese regenerative medicine revenue is indicated for 2027, leaving room for the start to slip further.

Funding · Share Count

The KRW 22.5 billion convertible bond issued in December 2025 could increase the share count if converted. With operating cash flow at KRW -10.2 billion in 2025 and R&D costs continuing, further fundraising remains possible. The company said it completed an investment round in early 2026.

11

What to watch next

  1. End of December 2026

    The end of the grace period under the pre-tax loss rule for management issue designation. Whether the ratio criteria are met will be confirmed through disclosures while losses continue.

  2. Early 2027

    Phase 2a data for EN001 are expected, according to NH Investment & Securities. This will be the basis for technology transfer talks and indication expansion.

  3. End of March 2027 (statutory filing deadline)

    The 2026 annual report is due. Full-year 2026 revenue, operating loss, debt-to-equity ratio, and convertible bond developments will be confirmed in the audited figures.

  4. 2027

    Whether Japanese regenerative medicine revenue ramps up and AAV and CAR-T orders show up in quarterly sales. It will also show whether revenue recovery translates into a smaller operating loss.

12

Overall view

ENCell's revenue fell from KRW 10.5 billion in 2023 to KRW 5.26 billion in 2025, while its operating loss widened from KRW 11.8 billion to KRW 17.9 billion, making it a loss-making company.

Q3 2026 revenue of KRW 1.71 billion rose for two straight quarters, but the operating loss of KRW 5.02 billion and the net loss attributable to controlling shareholders of KRW 5.78 billion have kept losses going for five straight quarters.

Bullish factors include a larger CDMO order backlog in AAV and CAR-T, EN001's Phase 2a progress with FDA and EMA orphan designations, and Japanese regenerative medicine certification.

Bearish factors include two straight years of falling revenue and wider losses, a rising debt-to-equity ratio after the KRW 22.5 billion convertible bond, and the missed IPO targets. On valuation, PER cannot be calculated given net losses over the last four quarters, while the price-to-book ratio is above 1.

The items to check are the end of the pre-tax loss grace period in late December 2026, EN001 Phase 2a data in early 2027, and full-year 2026 revenue and operating loss in the 2026 annual report due by March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. paxetv.com
  2. news.nate.com
  3. v.daum.net
  4. vegannews.co.kr
  5. etoday.co.kr
  6. bloter.net
  7. m.news.nate.com
  8. dailypharm.com
  9. m.dailypharm.com
  10. encellinc.com
  11. m.news.nate.com
  12. encellinc.com
  13. m.news.nate.com
  14. encellinc.com
  15. hankyung.com
  16. newspim.com
  17. m.news.nate.com
  18. v.daum.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis